131711-72-3

Upstream product

• 1397694-63-1 1(S),3(R)-bis(tertbutyldimethylsililoxy)-20(S)-hydroxy-9,10-secopregna-5,7(E),10⁽¹⁹⁾-triene 
• 1397694-62-0 1(S),3(R)-bis(tertbutyldimethylsililoxy)-9,10-secopregna-5,7(E),10⁽¹⁹⁾,17-tetraene 
• 1397694-61-9 1(S),3(R)-bis(tertbutyldimethylsililoxy)-20(R)-hydroxy-9,10-secopregna-5,7(E),10⁽¹⁹⁾-triene 
• 131830-01-8 1(S),3(R)-bis(tertbutyldimethylsililoxy)-20(R)-hydroxy-9,10-secopregna-5,7(E),10⁽¹⁹⁾-triene 
• 131711-71-2 1(S),3(R)-bis(tertbutyldimethylsililoxy)-20-one-9,10-secopregna-5,7(E),10⁽¹⁹⁾-triene 
• 112828-13-4 (5E,7E)-(1S,3R,20S)-1,3-bis<<(1,1-dimethylethyl)dimethylsilyl>oxy>-20-methyl-9,10-secopregna-5,7,10(19)-trien-21-al 

Downstream Products

• 152517-44-7 1(S),3(R)-bis(tertbutyldimethylsililoxy)-22-oxa-25-hydroxy-9,10-secocholesta-5(Z),7(E),10⁽¹⁹⁾-triene 
• 1397264-47-9 1(S),3(R)-bis(tertbutyldimethylsililoxy)-22-oxa-25-hydroxy-9,10-secocholesta-5(E),7(E),10⁽¹⁹⁾-triene 

Relevant academic research and scientific papers

POLYMORPHS OF MAXACALCITOL AND PROCESS FOR THE PREPARATION OF MAXACALCITOL

The present invention relates to Maxacalcitol polymorphs and Maxacalcitol having low residual solvent content as well as processes for their preparation. The present invention also relates to pharmaceutical compositions containing Maxacalcitol polymorphs or Maxacalcitol having low residual solvent content and treatment methods using the pharmaceutical compositions.